Literature DB >> 11428586

Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C.

Y Murawaki1, Y Ikuta, K Okamoto, M Koda, H Kawasaki.   

Abstract

PURPOSE: Chronic hepatitis C is an insidiously progressive disease, in which repeated assessment of liver histology is required. Various serum fibrotic markers have now been introduced. Our present aim was to assess, by receiver operating characteristic analysis, the usefulness of serum fibrotic markers for diagnosing fibrotic staging and necroinflammatory grading in chronic hepatitis C.
METHODS: Serum levels of procollagen type III N-terminal peptide (PIIINP), 7S fragment of type IV collagen (PIVNP), hyaluronan (HA), matrix metalloproteinase (MMP)-1, MMP-2, and tissue inhibitor of metalloproteinases (TIMP)-1 were measured in 169 patients with chronic hepatitis C.
RESULTS: The accuracy of these tests for discriminating stages greater than F2 from stages less than F1 was superior to that for discriminating stage F3 from stages less than F2. The most useful test for predicting stages greater than F2 was the serum HA test (cutoff value, 50 ng/ml; sensitivity, 75%; specificity, 80%), and the next-most useful was the serum MMP-2 test (cutoff value, 550 ng/ml; sensitivity, 75%; specificity, 70%). The usefulness of these tests for discriminating moderate grade from grades less than mild was superior to that for discriminating grades more than mild from minimal grade. The most useful test for predicting moderate grade was the serum HA test (cutoff value, 60 ng/ml; sensitivity, 77%; specificity, 74%), and the second-most useful was the serum PIVNP test (cutoff value, 6.5 ng/ml: sensitivity, 74%; specificity, 75%). The combination of the most useful and next-most useful test results increased the accuracy of the diagnosis of staging and grading.
CONCLUSIONS: These serum fibrotic markers, especially the serum HA test, would be clinically useful for assessing staging and grading in patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11428586     DOI: 10.1007/s005350170084

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  23 in total

1.  A new index for non-invasive assessment of liver fibrosis.

Authors:  Naohiro Ichino; Keisuke Osakabe; Toru Nishikawa; Hiroko Sugiyama; Miho Kato; Shiho Kitahara; Senju Hashimoto; Naoto Kawabe; Masao Harata; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Yuko Arima; Hiroaki Shimazaki; Koji Suzuki; Kentaro Yoshioka
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

2.  Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C.

Authors:  Agostino Colli; Alice Colucci; Silvia Paggi; Mirella Fraquelli; Sara Massironi; Marco Andreoletti; Vittorio Michela; Dario Conte
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

3.  Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis.

Authors:  Hong Sub Lee; Jai Keun Kim; Jae Youn Cheong; Eun Jin Han; So Yeon An; Jun Ha Song; Yun Jung Jung; Sung Chan Jeon; Min Wook Jung; Eun Jung Jang; Sung Won Cho
Journal:  Korean J Hepatol       Date:  2010-12

4.  Non-invasive diagnosis of liver fibrosis.

Authors:  Hiroyasu Morikawa; Norifumi Kawada
Journal:  Clin J Gastroenterol       Date:  2011-07-31

5.  Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha.

Authors:  Dariusz-Marek Lebensztejn; Maria-Elzbieta Sobaniec-Lotowska; Maciej Kaczmarski; Michael Voelker; Detlef Schuppan
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

Review 6.  Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

Authors:  Giada Sebastiani; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

7.  Correlation of serum liver fibrosis markers with severity of liver dysfunction in liver cirrhosis: a retrospective cross-sectional study.

Authors:  Cuihong Zhu; Xingshun Qi; Hongyu Li; Ying Peng; Junna Dai; Jiang Chen; Chunlian Xia; Yue Hou; Wenwen Zhang; Xiaozhong Guo
Journal:  Int J Clin Exp Med       Date:  2015-04-15

8.  Relationship between clinical and pathologic findings in patients with chronic liver diseases.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Jing-Yuan Fang; Ai-Ping Cao; Mo-Bin Wan; Cheng-Zhong Li; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

9.  Serum hyaluronic acid: a promising marker of hepatic fibrosis in chronic hepatitis B.

Authors:  Gamal Shiha
Journal:  Saudi J Gastroenterol       Date:  2008-10       Impact factor: 2.485

Review 10.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.